Lilly’s GLP-1 pill beats older Novo diabetes drug in head-to-head trial
Eli Lilly and Co. and Novo Nordisk have been locked in a fierce battle to control the obesity market, which is projected to reach $100 billion by the end of the decade.
Eli Lilly and Co.
Articles
FDA takes aim at Hims and other telehealth services in drug advertising crackdown
The Food and Drug Administration on Tuesday posted more than 100 letters to various drug and online prescribing companies, including Hims & Hers, which has built a multibillion-dollar business centered on lower-cost versions of blockbuster obesity injections.
Eli Lilly to build $5B plant in Virginia—first of 4 U.S. sites to be named this year
Indianapolis-based Lilly said the new plant would create more than 650 jobs in Virginia for engineers, scientists, operations personnel and lab technicians, as well as 1,800 construction jobs.
Lilly rival Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs
The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs.
World Health Organization adds Mounjaro to its list of essential medicines
The recommendation applies to a range of GLP-1 drugs that also includes Novo Nordisk’s Ozempic and Lilly’s older diabetes treatment, Trulicity.
Mounjaro price hike fuels UK pharmacy battle to retain customers
Eli Lilly and Co. announced this month it would raise the weight-loss treatment’s price by as much as 170%, presenting pharmacies with a dilemma about how much they would pass on to patients.
Lilly’s weight-loss pill moves ahead after pivotal trial
The company’s shares rose as much as 4.3% Tuesday after Eli Lilly announced the trial results for orforglipron.
Ireland’s exports to US plunge after tariff-induced surge, likely related to pharma stockpiling
Indianapolis-based Eli Lilly and Co. has operated in Ireland since the late 1970s and has more than 3,500 employees there.
Lilly signs $1.3B deal with Boston startup for AI-assisted drug development
Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes and obesity.
Lilly hikes obesity shot price in UK as Trump pressures drugmakers
Trump sent letters to 17 of the world’s largest drugmakers earlier this month, including Lilly and Novo Nordisk A/S, insisting they lower what they charge Medicaid in the U.S. for existing drugs.
Texas AG: Eli Lilly and Co. offered kickbacks to providers to prescribe blockbuster drugs
The complaint alleges the Indianapolis-based drugmaker offered illegal incentives to influence Texas providers to prescribe Lilly medications including Zepbound and Mounjaro.
Firm tied to Trump Jr. debuts direct sales product for pharma companies
Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand for direct sales. Lilly is working with Truepill and Amazon.com Inc.’s pharmacy unit on its platform.
UPDATE: Lilly shares tumble amid questions regarding weight-loss pill
The Indianapolis-based pharmaceutical giant released its second-quarter earnings Thursday along with data from the latest studies of its weight-loss pill, orforglipron.
Research on reversing Alzheimer’s reveals lithium as potential key
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.
More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects
Seventeen of the complaints also name Eli Lilly and Co. competitor Novo Nordisk Inc. as a defendant and make similar allegations about its GLP-1 drug, Ozempic.
Medicare, Medicaid plans to experiment with covering weight loss drugs
Trump administration officials have offered mixed messages about GLP-1s and whether they should be relied upon for weight loss by obese and overweight Americans.
Lilly’s Mounjaro gets mixed results in extensive study vs. Trulicity
A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results showed enough cardio benefits to eventually encourage investors.
Lilly gets limited European backing for Alzheimer’s drug
Lilly previously secured approval for Kisunla in the U.S., Japan and the U.K.
IBJ names 20 in their Twenties honorees for 2025
The up-and-coming leaders represent business, the arts and culture, philanthropy, government and community service.
Drugmaker telehealth deals risk unnecessary prescribing, Senate probe finds
Partnerships between telehealth companies and pharmaceutical giants Pfizer and Indianapolis-based Eli Lilly and Co. raise concerns about conflicts of interest and inappropriate prescribing, according to a Senate investigation released Thursday.